» Articles » PMID: 18848348

Outcome of Patients with Bladder Cancer with PN+ Disease After Preoperative Chemotherapy and Radical Cystectomy

Overview
Journal Urology
Specialty Urology
Date 2008 Oct 14
PMID 18848348
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Persistent nodal disease in the surgical specimen (pN+) after preoperative chemotherapy for urothelial carcinoma is associated with a poor prognosis. To improve our understanding regarding the outcomes of such patients, we performed a retrospective review of our experience.

Methods: From 1993 to 2003, 857 patients underwent radical cystectomy for urothelial carcinoma of the bladder, and 150 were found to have pN+ disease. Of these 150 patients, 37 had pN+ disease despite preoperative chemotherapy and formed the basis of this report. The survival data were analyzed using the Kaplan-Meier method and Cox regression analysis.

Results: The median patient age was 66 years (range 39-85), and the median follow-up was 50 months (range 13.0-58.7). The clinical stage at the initiation of preoperative chemotherapy was cT2 with lymphovascular invasion in 7, cT3b in 6, cT4a in 4, cT4b in 2, and cN+ in 18. The 2-year overall, disease-specific, and recurrence-free survival rate was 20%, 29.2%, and 13.5%, respectively. Of the 37 patients, 11 (30%) received adjuvant chemotherapy after surgery, most (73%) were platinum-based regimens. On Kaplan-Meier analysis, adjuvant chemotherapy was associated with improved recurrence-free and disease-specific survival. On multivariate analysis, surgical margin status, sex, and histologic type were significantly associated with overall survival, and the histologic type and use of adjuvant chemotherapy were significantly associated with recurrence-free survival.

Conclusions: Patients with persistent nodal disease despite preoperative chemotherapy have a poor prognosis. A cohort of such patients might do well with adjuvant chemotherapy. The lymph node density and pT category were not prognostic in patients with nodal metastasis after preoperative chemotherapy.

Citing Articles

Efficacy of Surgery on the Primary Tumour in Patients with Metastatic Bladder Cancer: A Comprehensive Review.

Lim A, Westerman M, Korokovic A, Matulay J, Narayan V, Navai N Bladder Cancer. 2024; 8(2):193-209.

PMID: 38993364 PMC: 11181818. DOI: 10.3233/BLC-211529.


Emerging Strategies in Adjuvant Immunotherapy: A Comparative Review of Bladder Cancer and Renal Cell Carcinoma Treatments.

Balli S, Bolek H, Urun Y Clin Med Insights Oncol. 2024; 18:11795549241257238.

PMID: 38827522 PMC: 11143815. DOI: 10.1177/11795549241257238.


Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+).

Malkiewicz B, Gurwin A, Karwacki J, Nagi K, Knecht-Gurwin K, Hober K Cancers (Basel). 2022; 14(21).

PMID: 36358705 PMC: 9656528. DOI: 10.3390/cancers14215286.


The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery.

Jeong H, Park K, Lee Y, Kim H, Kim J, Yoon S Cancer Res Treat. 2021; 54(1):226-233.

PMID: 33957019 PMC: 8756114. DOI: 10.4143/crt.2021.365.


Impact of Adjuvant Chemotherapy on Survival of Patients with Advanced Residual Disease at Radical Cystectomy following Neoadjuvant Chemotherapy: Systematic Review and Meta-Analysis.

Krajewski W, Nowak L, Moschini M, Poletajew S, Chorbinska J, Necchi A J Clin Med. 2021; 10(4).

PMID: 33567656 PMC: 7915645. DOI: 10.3390/jcm10040651.


References
1.
Winquist E, Kirchner T, Segal R, Chin J, Lukka H . Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol. 2004; 171(2 Pt 1):561-9. DOI: 10.1097/01.ju.0000090967.08622.33. View

2.
Abdel-Latif M, Abol-Enein H, El-Baz M, Ghoneim M . Nodal involvement in bladder cancer cases treated with radical cystectomy: incidence and prognosis. J Urol. 2004; 172(1):85-9. DOI: 10.1097/01.ju.0000132132.72351.4c. View

3.
Herr H, Faulkner J, Grossman H, Natale R, White R, Sarosdy M . Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004; 22(14):2781-9. DOI: 10.1200/JCO.2004.11.024. View

4.
Bono A, Benvenuti C, Reali L, Pozzi E, GIBBA A, COMUZZI U . Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group. Prog Clin Biol Res. 1989; 303:533-40. View

5.
SKINNER D, Daniels J, Russell C, Lieskovsky G, Boyd S, Nichols P . The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991; 145(3):459-64; discussion 464-7. DOI: 10.1016/s0022-5347(17)38368-4. View